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Edited by Vladimir SkulachevAbstract The intrinsic (mitochondria-dependent) pathway of
apoptosis is one of the major pathways leading to cell death. We
evaluated cytochrome c/apoptotic protease activation factor-1
(Apaf-1)-dependent activation of caspase-3 in brain and liver of
diﬀerent strains of rodents at diﬀerent stages of development. In
cell-free extracts from brain and liver of Sprague-Dawley rats,
caspase was activated by cytochrome c/2 0-deoxyadenosine 5 0-tri-
phosphate at both neonatal and adult stages. In adult brain ex-
tracts from Wistar rats, no activation of caspase was observed
while extracts from neonatal brain and liver and from adult liver
were activated. In CD-1 mouse, only neonatal extracts were acti-
vated. Alteration in levels of endogenous inhibitors of apoptosis
were not responsible for the lack of activation observed. Instead,
decrease in the content ofApaf-1 and caspase-3 and some degrada-
tion of caspase-9 during brain ageing were observed. These results
suggest that a decrease in apoptosis activation during ageing is not
tissue-speciﬁc, but rather displays a complex dependence on
species and strains of animals.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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pathway; Strain-dependent caspase activation1. Introduction
Cell death is critical for the development and orderly main-
tenance of cellular homeostasis in metazoans. Apoptosis is an
evolutionarily conserved cell death program executed by cys-
teine proteases (caspases) and regulated by the anti-apoptotic
members of the Bcl-2 protein family, among other regulators
[1,2].
The intrinsic pathway of apoptosis (IPA) is one of the main
apoptotic pathways, and is initiated by triggering events within
the cell, such as stress signals like DNA damage and hypoxia,Abbreviations: Apaf-1, apoptotic protease activation factor-1; cyt.c,
cytochrome c; dATP, 2 0-deoxyadenosine 5 0-triphosphate; DEVD-
AMC, acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin; IPA,
intrinsic pathway of apoptosis
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doi:10.1016/j.febslet.2006.05.066or the loss of survival signals [3,4]. A distinctive feature of this
pathway is the involvement of mitochondria, where the core of
the pathway is the apoptosome [5] consisting of cytochrome c
(cyt.c), 2 0-deoxyadenosine 5 0-triphosphate (dATP) and the
apoptotic protease activation factor-1 (Apaf-1), which pro-
motes the assembly of a caspase-activating complex [6]. The
role of cyt.c in apoptosis was recently established by the gener-
ation of ‘‘knock-in’’ mice expressing a cyt.c mutant (KA al-
lele), which retains normal electron transfer function but fails
to activate Apaf-1 [7]. It was widely accepted that Bcl-2 protein
also prevented cyt.c release by safeguarding the mitochondrial
membrane integrity; however, it seems that Bcl-2 can also reg-
ulate a caspase activation programme independently of the
cyt.c/Apaf-1/caspase-9 ‘apoptosome’, which appears to ampli-
fy rather than initiate the caspase cascade [8].
The implication of mitochondria in apoptosis has important
consequences for the understanding of the normal physiology
of cell death, its deregulation in cancer and degenerative dis-
eases, and the development of novel cytotoxic and cytoprotec-
tive drugs [9–11].
However, there is increasing evidence for the lack of activa-
tion of the intrinsic pathway under physiological [12,13] and
pathological [12,14–16] conditions.
In order to understand the regulation of the IPA during age-
ing, we assessed several factors that could inﬂuence its activa-
tion in rodents: developmental stage, tissue speciﬁcity, genetic
background, potential upregulation of endogenous inhibitors
of apoptosis and regulation of the components of the apopto-
some complex.2. Materials and methods
All chemicals were of analytical grade and were purchased from Sig-
ma–Aldrich unless otherwise stated.2.1. Preparation of cell-free extracts from tissues
Healthy rodents, namely CD-1 mouse, Sprague-Dawley and Wistar
rat strains were purchased from Charles River Laboratories and paired
at the vivarium of the Buck Institute. The experimental animals used in
these studies were handled according the NIH Guide for the care and
use of Laboratory Animals and the Institutional Animal Care and Use
Committee (IACUC) policies.
The animals were selected at various stages of maturation. The fetus
were 14–16 days old, neonatal ranged from birth to 24 h after birth,
young from 15 to 30 days old, adult from 3 to 4 months and old from
8 to 12 months old. The animals were euthanized on a carbon dioxide
chamber prior to use. All steps were carried at 4 C unless otherwise
stated. The selected organ was immediately removed, washed with
ice-cold PBS, chopped and homogenized at the appropriate ratio inblished by Elsevier B.V. All rights reserved.
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3740 V. Stoka et al. / FEBS Letters 580 (2006) 3739–3745hypotonic buﬀer (20 mM PIPES buﬀer, pH 7.4, containing 10 mM
KCl, 5 mM sodium EGTA, 2 mM MgCl2 and 1 mM dithiothreitol).
Fetal and neonatal brain tissue were homogenized in a glass homoge-
nizer (KONTES) and a teﬂon pestle homogenizer (KONTES) was
used for the other tissues. Debris and nuclei were removed by centrifu-
gation at 1000 · g for 10 min. The supernatant was further centrifuged
at 16000 · g for 30 min and the pellet was discarded. The S16 extract
was aliquoted and stored at 80 C.
For Western-blotting, a cocktail of inhibitors (Roche) was added in
order to prevent unwanted proteolysis.
2.2. Determination of protein concentration
Protein concentration was determined using a Coomassie plus pro-
tein reagent (Pierce) based on a Bradford assay. The measurements
were done on a Shimadzu UV-2401PC spectrophotometer calibrated
using a bovine serum albumin standard curve.
2.3. Caspase activation
The kinetics of activation was performed as described [17]. The eﬀect
of cyt.c/dATP non-activatable extract on IPA activation was studied as
following: based on the response of S16 cell-free extracts to cyt.c/dATP
activation, two types of extracts were found. Activatable extract (A) re-
sponded positively to cyt.c/dATP activation and was found in neonate
extracts whereas the non-activatable ones (NA) were resistant to cyt.c/
dATP activation and were found mainly in adult tissue extracts.
Five microliters of neonate CD-1 mouse brain (or liver) cell-free ex-
tracts were incubated with increasing volumes (5–40 ll) of adult mouse
brain (or liver) cell-free extracts during 60 min at 37 C. The samples
were then activated with 10 lM cyt.c and 1 mM dATP for 30 min at
37 C in a reaction volume of 90 ll.
Granzyme B activation was studied by addition of the enzyme
(Sigma, #G9278) (0.1 lM ﬁnal concentration) to 50 lg of S16 extract
of mouse brain tissue. A control experiment in the absence of gran-
zyme B was run under the same conditions. In both cases, the reaction
was started by addition of 10 ll of Ac-DEVD-AMC (acetyl-Asp-Glu-
Val-Asp-7-amino-4-methylcoumarin) substrate (Anaspec, #25262)
(50 lM ﬁnal concentration) and the residual activity was monitored
continuously for 30 min at 37 C in a thermostated Molecular Devices
SpectraMax Gemini spectroﬂuorimeter, at excitation and emission
wavelengths of 370 and 460 nm. The steady-state rates of substrate
hydrolysis were obtained from the linear parts of the curves. Activa-
tion was measured in terms of DEVDase activity and expressed in rel-
ative units of ﬂuorescence (RU), except in the granzyme activation
experiment where the results were expressed in lM/min and standard-
ized using a calibration curve based on known concentrations of AMC
(7-amino-4-methylcoumarin) ﬂuorogen (Anaspec, #23482). Means ±
S.D. were calculated from independent measurements of three diﬀerent
lysates.
2.4. Electrophoresis and Western blotting
Electrophoresis and Western blotting were carried out on the Nu-
PAGE Bis-Tris system following the instructions provided by the sup-
plier (Invitrogen). Positive controls for caspases -9 and -3 consisted of
cell free extracts of HEK 293T overexpressing cells. The following anti-
bodies were used: Apaf-1 antibody (QED Bioscience, #2015), anti-cas-
pase-9 (Santa Cruz Biotechnology, #H-83), anti-caspase-3 (Santa Cruz
Biotechnology, #H-277), and horseradish peroxidase (HRP)-conju-
gated goat anti-rabbit antibody (Santa Cruz Biotechnology). The
protein/antibody complexes were detected using enhanced chemilumi-
nescence (ECL) Plus Western Blotting Detection Reagents (Amersham
Biosciences, #RPN2132). Densitometric analysis was carried out using
the NIH Image J software at http://rsb.info.nih.gov/nih-image/. The y-
axis represents protein relative area quantiﬁed at each maturation
stage. Means ± S.D. were calculated from three repeated measure-
ments of density from the same experiment.neonate adult neonate adult
Fig. 1. Cyt.c/dATP activation of brain and liver extracts of Sprague-
Dawley rat (A), Wistar rat (B) and CD-1 mouse (C). Brain and liver
cell-free extracts of neonatal and adult rodents (20 lg/ll protein
concentration) were activated with cyt.c/dATP. A control experi-
ment was carried out in the absence of cyt.c/dATP. The control and
cyt.c/dATP treated samples are indicated by open and ﬁlled bars,
respectively.3. Results and discussion
We recently reported that the cyt.c/dATP activation of cell-
free extracts of primary cortical neurons is age-dependent,
whereas extracts of astrocytes were activated to a similarextent at all stages evaluated [17]. In the current work, we eval-
uated the eﬀects of several factors that might inﬂuence the acti-
vation of the caspase cascade, such as the rodent’s genetic
background, tissue speciﬁcity, developmental stage and the
presence and activity of endogenous inhibitors of apoptosis.
Out-bred rodents, Sprague-Dawley and Wistar rats and CD-
1 mice, were used in these studies. Liver and brain tissues were
chosen as mitotic and post-mitotic models, respectively. The
rodents’ ages were postnatal day 1 (neonate) and 4-month-
old (adult), respectively. Sprague-Dawley brain and liver ex-
tracts were activated by cyt.c/dATP to diﬀerent extents at both
developmental stages (Fig. 1A). In contrast, no activation was
observed in Wistar brain extracts (Fig. 1B) or in both adult
CD-1 extracts (Fig. 1C). The pattern of activation of the
V. Stoka et al. / FEBS Letters 580 (2006) 3739–3745 3741‘IPA’ was diﬀerent in the three rodents studied (Fig. 1). These
diﬀerences were therefore quantiﬁed for each organism. De-
grees of activation in brain and liver were compared at both
developmental stages (neonate and adult) and for each devel-
opmental stage (neonate or adult) both tissues (brain and liver)
were compared. In Sprague-Dawley rats, the neonate: adult ra-
tio for the IPA activation was 10-fold in brain and 1.5-fold in
liver cell-free extracts, respectively (Fig. 1A). The correspond-
ing ratios were 48-fold and 2.8-fold in Wistar rats (Fig. 1B)
and 54-fold and 17-fold in CD-1 mice (Fig. 1C). In neonatal
extracts the IPA activation was greater in brain than in liver
by factors of 2.2-fold in Sprague-Dawley (Fig. 1A), 1.5-fold
in Wistar (Fig. 1B) and 3.2-fold in CD-1 strains (Fig. 1C). In
contrast, for adult animals, the liver:brain ratio for IPA activa-
tion was 3.2-fold for Sprague-Dawley (Fig. 1A), 11-fold for
Wistar (Fig. 1B) strains; no activation was observed in CD-1
mice in either tissue (Fig. 1C).
The fact that cyt.c/dATP activation showed a distinct pat-
tern in all three rodents evaluated (Fig. 1) suggests that the
lack of activation of the IPA is not clearly tissue-speciﬁc or
age-speciﬁc, but that the strain background appears to be a
major determinant. Our ﬁndings indicate that the IPA does
not demonstrate a completely consistent pattern, being neither
tissue-speciﬁc, as previously suggested [13], nor uniformly age
dependent; rather, it is strain-dependent and species-dependent
(Fig. 1). These data are compatible with those of a recent re-
port that showed that, in certain strains of caspase-9, Apaf-1
or cyt.c-ablated mice, alternative cell death routes are avail-
able, despite the growth and developmental abnormalities
observed in these mice [7].
Recently, strain-dependent diﬀerential susceptibilities to cell
death stimuli that target the intrinsic [7, this work] and/or the
extrinsic [18] apoptotic pathway have been reported. For
example, cortical cultures from the inbred mouse strain
C57BL/6 exhibited a 28% greater neuronal death following
doxorubicin treatment than C57BL/10, and the greater resis-
tance to death receptor-mediated apoptotic cell death of the
latter was related to Fas, FasL, and MMP expression [18].
In addition, the importance of the strain selected was found
to be crucial to the phenotype observed [19,20]. A detailed
study aimed to uncover the importance of various genes to
apoptosis in the ovary was carried out in one outbred (CD-
1) and several inbred (129/Sv, DBA/2, C57BL/6, FVB, AKR/
J) strains of mice at day 4 (neonatal) and day 42 (young adult)
postpartum [21]. In the absence of genetic manipulation the
size of the primordial oocyte reserve was aﬀected by mouse
strain whereas genetic modiﬁers play a major role in follicle
endowment, development and atresia in the mouse ovary
[21]. Therefore, strain-dependent diﬀerences in response to
apoptotic stimuli should be taken into consideration when
developing transgenic models to understand the molecular
basis of disease.
Since the response to cyt.c/dATP activation of the diﬀerent
extracts studied here diﬀered signiﬁcantly, we hypothesized
that resistance of an extract to cyt.c/dATP activation might
be caused by the presence of an endogenous inhibitor. Numer-
ous such inhibitors exist, such as the IAP (inhibitor of apopto-
sis) proteins (e.g., IAP-1, IAP-2, NAIP, XIAP, and survivin)
[22], some Bcl-2 family members, some chaperones, and oth-
ers. Previous results have indicated that alterations in such
inhibitors underlie apoptotic shifts in some pathological condi-
tions: for example, degradation of cellular IAP-1 and XIAPwas found in post-mortem Huntington’s disease brain tissue,
in association with an excess of apoptosis [23]. On the other
hand, IAP-2 conferred resistance to apoptosis in hypoxic cells
[24]. In addition, in a study carried out on 6- and 26-month-old
Fischer 344 rats it was found that caloric restriction may pro-
vide neuroprotection to the ageing brain by partially suppress-
ing the activation of caspase-3 and PARP cleavage, and by
further upregulating XIAP inhibitor, the latter probably in-
volved in the increased resistance to apoptosis observed in
caloric restricted animals [25].
The anti-apoptotic Bcl-2 protein was reported to be respon-
sible for the cardiac ﬁbroblast resistance to apoptosis [26]. On
the other side, despite low Bcl-2 levels, senescent cells develop
resistance to apoptosis, even though no signiﬁcant changes
were observed between the ratio of anti- and pro-apoptotic
proteins [27]. Since senescent cells are halted permanently in
the G0/G1-phase of the cell cycle, their resistance to cell death
was argued to be related to their non-cycling nature [27]. Thus,
numerous strategies have been shown to be utilized by diﬀer-
ent cell types, under diﬀerent conditions, to achieve modula-
tion of the activation of apoptosis, and in some cases these
involve an upregulation of apoptosis inhibitors such as the
IAP proteins.
Therefore, to evaluate the hypothesis that the observed de-
cline in IPA activation may be due to the age-related upregu-
lation of apoptotic inhibitors, we performed mixing studies to
reveal the possible presence of inhibitors of caspase activation.
Two extracts originating from the same strain and tissue, dif-
fering only in the stage of development, were incubated for
60 min at 37 C. The extract from the neonate (extract A)
was eﬀectively activated by cyt.c/dATP, whereas that from
the adult (extract NA) was cyt.c/dATP resistant (Fig. 2A).
The two extracts were mixed in diﬀerent proportions, the eﬀect
of cyt.c/dATP observed for 30 min, and residual activities
monitored on a spectroﬂuorometer after addition of the sub-
strate. At a 1:1 ratio (v/v) no inhibitory eﬀect was observed
in mouse brain or mouse liver, since the activities of the acti-
vatable and non-activatable mixture (A + NA) were of the
same magnitude as that observed for the A fraction
(Fig. 2A). In order to exclude the possibility of the lack of inhi-
bition being due to a potential component being at a low con-
centration in the NA extract, increasing volumes of the NA
extract (5–40 ll) were added, and found to cause no inhibitory
eﬀect on the A fraction (Fig. 2B). An analogous pattern was
obtained for brain extracts of Sprague-Dawley and Wistar
strains (results not shown), thus further conﬁrming that endog-
enous inhibitors were not responsible for the observed decrease
in IPA activation.
The Apaf-1 Æ cyt.c complex is the functional apoptosome
that activates procaspase-9 [6]. Therefore, Apaf-1 expression
was examined as a function of brain ageing by Western blot-
ting. After the neonatal stage, a 130 kDa band corresponding
to the Apaf-1 precursor, as detected with Apaf-1 antibody
raised against residues 1158–1177 of Apaf-1 molecule, was less
intense, indicating either downregulation or proteolytic cleav-
age (Fig. 3A, lanes 4–6). Apaf-1 expression observed at the
neonatal stage was 2-fold greater than at the following stages
(Fig. 3B) thus being at least one of the causes of the lack of
activation observed (Fig. 1). The deﬁciency or absence of
Apaf-1 was found to confer resistance to cyt.c-dependent
apoptosis [12,14,16,28]. Apaf-1 inactivation has been reported
as being due to methylation [15] and caspase-3 cleavage
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Fig. 2. Eﬀect of an extract non-activatable by cyt.c/dATP on caspase
activation. The experiment was carried out on CD-1 mouse extracts as
described in Section 2.3. The activatable extract (A) was from neonatal
and the non-activatable (NA) from adult tissues. (A) Eﬀect of a non-
activatable extract on an activatable one for brain and liver at a ratio
1:1 (v/v). (B) Eﬀect of concentration of NA extract on the IPA
activation. Brain extracts were used at ratios of 1:1, 1:2, 1:4 and 1:8
(v/v). The activatable extracts (A) are indicated by a ﬁlled bar, the
non-activatable (NA) by an open bar, and the mixtures of activatable
and non-activatable extracts (A + NA) by a grey bar.
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Fig. 3. Expression proﬁle of Apaf-1 during brain ageing. (A) Fifty
micrograms of mouse brain cell-free extracts at several stages of
maturation: fetus (lane 2), neonate (lane 3), young (lane 4), adult (lane
5) and old (lane 6) were subjected to electrophoresis and Western
blotting. The positive control consisted of a cell-free extract of HEK
293T cells overexpressing Apaf-1 (lane 1). (B) The Apaf-1 band
intensities in (A) were determined as stated in Section 2.4.
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been conﬁrmed in gene-targeted Apaf-1/ mice which exhib-
ited brain overgrowth and severe craniofacial malformations
[31,32]. The latter were linked to the forebrain overgrowth
mutation (fog) involved in the pathogenesis of spina biﬁda, a
common congenital malformation [33]. Other alterations in-
cluded male infertility [34], persistence of interdigital webs
and dramatic alterations of the lens and retina [32].
In the same extracts we also measured the protein expression
of the two main regulators of the pathway, namely caspases -9
and -3 (Figs. 4A and 5A). Caspase-9 antibody recognized the
46 kDa precursor form (pro-C9), a major band of
35 kDa and a minor band of 11 kDa (Fig. 4A, lane 1).
C9 p35 (the 35 kDa band) includes the enzyme linker region
(Asn92-Leu151, 6446.37 Da) bound to its catalytic domain
(Ala152-Ser416, 29199.22 Da). The 11 kDa band corresponds
to the small subunit (C9 p11) (Ala316-Ser416, 11548.11 Da).
The 4 kDa diﬀerence between human [35] (Fig. 4A, lane 1)
and mouse [36] (Fig. 4, lanes 2–6) caspase-9 zymogens is due
to the 38 amino acids shorter linker region in the former. Se-
quence alignment of the two primary structures indicated
72% amino acid identity (results not shown). The antibody
raised against human caspase-9 C-terminus epitope cross-re-
acted with the mouse counterpart and showed the 50 kDa
precursor form (pro-C9), a minor band of 29 kDa corre-sponding to the catalytic domain (C9 p29) (Tyr191-Ser454,
29233 Da) and a major band of 11 kDa corresponding to
the small subunit (C9 p11) (Ala354-Ser454, 11373.98 Da)
(Fig. 4A, lanes 2–6). During the course of brain ageing the
expression of caspase-9 zymogen decreased 1.5-fold after
birth (Fig. 4A, lanes 4–6; Fig. 4B). The zymogen was activated,
as seen by the 2-fold increase in the expression levels of the
enzyme small subunit (Fig. 4A, lanes 2–6; Fig. 4D) and the cat-
alytic domain (Fig. 4A, lanes 4–6; Fig. 4C). The fact that the
antibody used was raised against the small subunit could ex-
plain the lower recognition seen by the catalytic domain
(Fig. 4A, lanes 4–6). Steric hindrance of the catalytic domain
by the enzyme’s large subunit was excluded because, on elec-
trophoresis, the sample was run under denaturing conditions.
In a previous study on rat cortex using a monoclonal 5B4
anti-caspase-9 antibody (Medical and Biological Laboratories)
that recognizes both rat procaspase-9 and its large subunit,
nearly complete cleavage of procaspase-9 was shown in E17
(embryonic day 17), P2 (postnatal day 2) and P7 extracts,
whereas the degree of caspase-9 cleavage was markedly de-
creased in P14 extracts and was not detected in P60 extracts
[12]. Our results are in agreement with the zymogen pattern,
however, the diﬀerences in the large subunit pattern could be
due to the facts that we monitored animals up to 8 months
old and we used a diﬀerent antibody. In addition, the studies
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Fig. 5. Expression proﬁle of caspase-3 during brain ageing. (A)
Representative Western blot of 50 lg of cell-free extracts of mouse
brain tissue at various stages of maturation: fetus (lane 2), neonate
(lane 3), young (lane 4), adult (lane 5) and old (lane 6). A positive
control consisted of 50 lg of HEK 293T cells overexpressing caspase-3
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Fig. 6. Direct activation of the apoptotic pathway during brain ageing.
Fifty micrograms of cell-free extracts of mouse brain tissue at several
stages of maturation, fetus, neonate, young, adult and old were
activated by addition of granzyme B. A control experiment in the
absence of activator was run under the same conditions. Caspase
activation was measured ﬂuorometrically as described in Section 2.3.
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mouse strain. In the previous report [12] the authors used rat
cortex and stated that similar age-dependent changes in
cyt.c-dependent apoptotic susceptibility were found in devel-
oping mouse brain [12].Caspase-3 was evaluated by two independent methods, Wes-
tern blotting (Fig. 5A) and kinetics, using the serine protease
granzyme B as direct activator (Fig. 6). During brain ageing,
procaspase-3 was shown to be structurally intact, as seen by
the 32 kDa precursor form (pro-C3) (Fig. 5A, lanes 2–6).
However, the zymogen expression was downregulated 3-fold
(Fig. 5B). In order to conﬁrm the enzyme functionality, the
extracts were induced with the canonical serine protease gran-
zyme B [37]. Procaspase-3 was activated in the range of 52–
213-fold at all stages of brain maturation (Fig. 6), in agreement
with the enzyme expression levels (Fig. 5A, lanes 2–6; Fig. 5B).
The positive control consisted of an extract of HEK 293T cells
3744 V. Stoka et al. / FEBS Letters 580 (2006) 3739–3745overexpressing caspase-3. The antibody recognized two addi-
tional bands of 20 kDa and 11 kDa corresponding to the
enzyme large (C3 p20) and small (C3 p11) subunits (Fig. 5A,
lane 1) which resulted from a cleavage at Asp175/Ser176 [38].
Human and mouse caspase-3 zymogens are 85% amino acid
identical (results not shown). The lack of activation of this
pathway may be due to enzyme downregulation (Fig. 5A, lanes
2–6) or to the enzyme functionality being compromised. The
lack of function due to alternative inactivating cleavages was
excluded because, by Western blotting, we conﬁrmed the en-
zyme’s intactness (Fig. 5A, lanes 2–6). Caspase-3 downregula-
tion represents a major regulatory step during brain ageing
because it turns-oﬀ not only the ‘intrinsic’ but also the ‘extrin-
sic’ pathway. Downregulation of caspase-3 has been observed
under physiological [13,17,39] and pathological conditions
[12,40]. In addition, this experiment excludes the possibility
of random lack of activation of some adult extracts, since it in-
volves the serine peptidase granzyme B which directly activates
executioner caspases [37]. It appears therefore that the resis-
tance to cyt.c/dATP activation is cell-dependent and that there
is no unique pathway.
In conclusion, our results indicate that the rodent’s genetic
background and developmental maturity play crucial roles in
IPA activation/inactivation, not simply the tissue speciﬁcity,
as previously suggested [13]. Furthermore, the age-related de-
cline in IPA activation was found not to be the result of the
upregulation of dominant inhibitors such as IAPs. Instead,
the results are most compatible with the decline in apoptotic-
activating proteins such as Apaf-1, caspase-9 and caspase-3,
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